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Abstract 
Introduction: Purpura fulminans (PF) is a devastating complication of uncontrolled 
systemic inflammation, associated with high incidence of amputations, skin grafts and 
death. In this study, we aimed to clarify the clinical profile of pediatric patients with PF 
who improved with protein C (PC) treatment, explore treatment effects and safety, 
and to refine the prognostic significance of protein C plasma levels. 
Methods: In Germany, patients receiving protein C concentrate (Ceprotin
®, Baxter 
AG, Vienna, Austria) are registered. The database was used to locate all pediatric 
patients with PF treated with PC from 2002 to 2005 for this National, retrospective, 
multi-centered study. 
Results: Complete datasets were acquired in 94 patients, treated in 46 centers with 
human, non-activated protein C concentrate for purpura fulminans. PC was given for 
2 days (median, range 1-24 days) with a median daily dose of 100 IU/kg. Plasma 
protein  C  levels  increased  from  a  median  of  27%  to  a  median  of  71%  under 
treatment.  22.3%  of  patients  died,  77.7%  survived  to  discharge.  Skin  grafts  were 
required  in  9.6%,  amputations  in  5.3%.  PF  recovered  or  improved  in  79.8%, 
remained  unchanged  in  13.8%  and  deteriorated  in  6.4%.  Four  adverse  events 
occurred in 3 patients, none classified as severe. Non-survivors had lower protein C 
plasma levels (P < 0.05) and higher prevalence of coagulopathy at admission (P < 
0.01). Time between admission and start of PC substitution was longer in patients 
who died compared to survivors (P = 0.03). 
Conclusions: This retrospective dataset shows that, compared to historic controls, 
only  few  pediatric  patients  with  PF  under  PC  substitution  needed  dermatoplasty 
and/or amputations. Apart from epistaxis, no bleeding was observed. Although the 
data comes from a retrospective study, the evidence we present suggests that PC 
had a beneficial impact on the need for dermatoplasty and amputations, pointing to 
the potential value of carrying out a prospective randomised controlled trial.    
Introduction 
Dermal  and  systemic  thrombosis  of  the  microcirculation,  referred  to  as  Purpura 
fulminans (PF), is a devastating complication of widespread endothelial destruction 
due  to  uncontrolled  systemic  inflammation,  associated  with  a  high  incidence  of 
multiple  organ  failure,  need  for  amputations,  skin  grafts  and  death.  PF  most 
frequently occurs in the pediatric age group, with a peak incidence in infants (1 to 3 
years of age) and adolescents (16 – 18 years of age). Although most frequently seen 
in the context of severe septic shock, in particular in patients with meningococcemia, 
PF also occurs in the rare scenario of homozygous or double heterozygous Protein C 
(PC) deficiency [1]. Indeed, the clinical manifestation of a severe PC deficiency in the 
form of PF has resulted in the description of PF as the clinical symptom of an acute 
PC pathway failure [2]. Consequently, many intensivists have used PC substitution in 
patients with PF, mostly with promising results [3-6]. The biological rationale for this 
use  was  the  anti-coagulant,  anti-inflammatory,  pro-fibrinolytic,  anti-apoptotic  and 
barrier  enhancing  action  of  PC  [7-10].  This  retrospective  multi-centered  study 
analyzes  clinical  features,  safety  and  outcome  in  94  pediatric/adolescent  patients 
with PF who received a human non-activated PC concentrate as rescue therapy in 
Germany from 2002 - 2005. In this study, we aimed to clarify the clinical profile of 
pediatric patients with PF who improved with PC treatment, explore treatment effects 
and  safety,  and  to  refine  the  prognostic  significance  of  Protein  C  plasma  levels. 
Finally,  this  study  will  help  to  establish  hypotheses  and  endpoints  for  future 
prospective studies on human Protein C in patients with PF. 
 
    
Materials and methods 
The ethics committee of the J.W. Goethe University, Frankfurt, Germany approved 
the study protocol for this retrospective, multi-center study. Patients who received a 
human plasma-derived, virus-inactivated Protein C concentrate (Ceprotin®, Baxter 
AG, Vienna, Austria) in Germany were registered by the manufacturer due to a post-
marketing commitment requested by the European Medicines Agency. This German 
database was used to locate all pediatric patients treated with PC concentrate from 
2002 – 2005. The flow of the patients throughout the study is displayed in Fig. 1. If a 
patient who received PC concentrate was identified, the principal investigator, with an 
invitation to participate in the study, contacted the treating physician. If the treating 
physician  agreed  to  participate,  the  hospital  was  visited  by  a  medical  monitor 
(physician)  for  standardized  (clinical  reporting  form  based)  data  collection.  For 
analysis, patients were stratified into three outcome groups by survival to hospital 
discharge  and  complications  (negative  outcome:  death  and/or  amputation, 
intermediate  outcome:  survival  with  skin  grafts/dermatoplasty,  positive  outcome: 
survival without amputations or skin grafts). Since data was collected on anonymized 
forms, the ethics committee waived the need for informed consent by the patient or 
relatives.  
Statistics:  Descriptive  statistics  were  used  for  categorical  (tables,  rates,  95% 
confidence intervals) and continuous (quartiles, minimum, maximum, mean, standard 
deviation) variables. Differences in categorical variables between groups were tested 
by  the  Chi-square  test.  Differences  in  continuous  variables  between  groups  were 
tested  by  the  non-parametric  Mann-Whitney  U  Test.  Comparisons  of  relevant 
parameters were performed between survivors and non-survivors. The relevance of 
Protein C plasma levels at admission on the probability to survive the disease was 
assessed by a logistic regression and an odds ratio was calculated to quantify the 
influence  of  the  level  of  Protein  C  plasma  activity  at  admission  on  survival  to 
discharge.  
Role  of  the  funding  source:  Baxter  Deutschland  GmbH,  Heidelberg,  Germany, 
financially supported this Study. AV and RS designed the study. All authors had full 
and unrestricted access to the complete dataset. Baxter had no influence on the data 
selection, interpretation or publication.  
 
    
Results 
Demographics: 102 patients were located, 94 of those entered the final analysis (Fig 
1). 52 (55.3%) were male, 42 (44.7%) female. 8 (8.9%) patients were newborn (< 28 
days old), 36 (38.3%) infants (28 days – 2 years), 29 (30.9%) children (2 – 12 years) 
and 21 (22.3) adolescents (12 – 18 years).  
Patients were treated in 46 different centers, with 36 centers treating 2 patients or 
less and 10 centers treating 3 or more patients. None of the centers participated in or 
recruited pediatric patients for treatment studies with activated Protein C (drotrecogin 
alfa, Xigris®) at the time of this study. 
Origin of PF: PF was the result of acquired sepsis rather than congenital Protein C 
deficiency in all patients. Neisseria meningitides was isolated in 75 (79.8%), in 52 of 
those sero-groups were specified.  
Survival and Outcome of PF: 21 patients (22.3%) died at a mean duration of 2 
days, 73 (77.7%) survived to discharge. There was no significant difference in age or 
gender between survivors and patients who did not survive. Skin grafts were required 
in 9 (9.6%) and amputations in 5 (5.3%) patients.  
PF recovered or improved in 75 patients (79.8%), remained unchanged in 13 (13.8%) 
and deteriorated in 6 (6.4%). 
Shock: At admission, no difference in mean arterial pressure (MAP) was detected 
between survivors and non-survivors (median 61.5 vs. 70mmHg, p=0.168). However, 
already  at  admission,  survivors  presented with  lower  heart  rates  (median  150  vs. 
185bpm,  p=0.0132)  higher  Glasgow  Coma  Scale  scores  (mean  12.5  vs.  9.9, 
p=0.027) and less negative base excess compared to non-survivors (median -4.95 
vs. -11.85mmol/l, p=0.021). 
A total of 63 patients received inotropic support for a median duration of 2 days. 
Protein C treatment: Non-survivors had significantly lower Protein C plasma activity 
at admission than survivors (median 10 vs. 30%, p = 0.011).  A higher level of Protein 
C plasma activity by 1% at admission improved the odds to survive significantly (p = 
0.0285) by a factor of 1.06 (95% CI for OR [1.01; 1.12]). PC was given for a median 
of 33 hrs (range 1 - 645 hrs) with a median daily dose of 100 IU/kg (range 28 – 375 
IU/kg). PC was administered as a bolus every 4 to 6 h in 78 patients, and as an initial 
bolus followed by continuous infusion in the remaining 16 patients. There was no 
significant  difference  in  survival  between  the  bolus  group  (21.8%  died)  and  the 
bolus+infusion group (25.0% died; p=0.961).  Plasma protein C levels increased from    
a median of 27% (range 1 – 75%) prior to PC treatment to a median of 71% under 
treatment (range 14 – 184%, Table 1). Once under PC substitution, there was no 
significant difference in plasma Protein C levels between survivors and non-survivors 
(p = 0.605). 
The time interval between admission and the start of PC substitution was significantly 
longer (median 8.6 hrs vs. 4 hrs, p = 0.03) in patients who died compared to those 
who  survived,  and  also  longer  in  patients  who  had  amputations  and/or  died 
compared to those who fully recovered (median 9.25 hrs vs. 4 hrs, p = 0.016).  
Inflammatory Response: C-reactive protein (CRP) levels were significantly lower at 
admission in non-survivors compared to survivors (Median: 5.9 mg/dl vs. 11.6 mg/dl, 
p  =  0.002),  white  blood  cell  counts  were  also  lower  on  admission  and  during 
treatment  in  the  non-survivors,  but  this  trend  did  not  reach  statistical  significance 
(Table 1).  
Coagulopathy:  Non-survivors  showed  a  significantly  higher  prevalence  than 
survivors of coagulopathy with prolonged activated partial thromboplastin time (aPTT) 
at admission (Median: 108 sec. vs. 52 sec., p < 0.0001). A significantly higher rate of 
coagulopathy was still documented under PC treatment in the non-survivors (Table 
1). The platelet count did not differ significantly at admission between survivors and 
non-survivors;  however,  during  treatment,  survivors  showed  significantly  higher 
platelet counts than patients who died (Median: 103 G/l vs. 61 G/l, p = 0.0047).  
Fresh frozen plasma: 71 out of the 94 received fresh frozen plasma (FFP). 45% 
received  one  FFP  transfusion,  30%  two  and  25  %  received  3  or  more  FFP 
transfusions.  The  total  amount  FFP  given  was  33,3  ml/kg  in  patients  being 
transfused, on day one 20 ml/kg in median, on day two 22 ml/kg in median and on 
day three 13 ml/kg in median. There was no difference in survival between those 
patients  transfused  compared  to  those  who  did  not  receive  FFP  (p  =  0.345). 
However, there was a trend towards a better survival in those patients receiving high 
volume  (=/> 25 ml/kg/d) FFP on day one compared to those who received less or no 
FFP (p = 0.069).   
Length of stay and mechanical ventilation: Length of stay on the intensive care 
unit was 8 days in median (1 – 95 days) in the whole group, 2 days in median for 
non-survivors  and  9  days  in  median  for  survivors  (p<0.0001).  The  duration  of 
mechanical  ventilation  was  6.5  days  in  median for  those  who  survived.  Survivors    
were discharged out of hospital after 18 days in median, non-survivors had a median 
hospital stay of 2 days.  
Adverse Events and Hemorrhage: Four adverse events (AE) were reported in 3 
patients.  None  was  classified  as  severe  by  the  treating  physician  (2  events  of 
haemorrhage from nose and/or throat, 1 event of pleural effusion, 1 event of transient 
increase in body temperature). The first patient with an AE developed bleeding from 
the nose 6 hrs after receiving 66 IU/kg PC. The bleeding stopped spontaneously after 
1hrs and the patient received the next scheduled dose 2 hrs after the onset of the 
event without further complications. The treating physician classified the severity as 
moderate and causative relation to PC treatment as unknown. The second patient 
was a severely coagulopathic child, who developed hemorrhage from the throat and 
nose  immediately  after  a  difficult  endo-tracheal  intubation  approx.  13  hrs  after 
receiving 83 IU/kg PC. The patient received the next dose as scheduled 4 hrs after 
the  event  without  further  complications.  The  same  patient  developed  a  pleural 
effusion (serous with later blood staining) more that 24 hrs after the PC therapy was 
ceased. The treating physician classified the severity of both events as moderate, a 
causative relation to PC treatment as unlikely.  A third patient showed a transient (10 
min)  and minor  increase  in  body  temperature  (from  39.0C  to  39.5C)  shortly  after 
receiving 100 IU/kg PC. No treatment was required; the treating physician classified 
the severity as mild.   
    
Discussion 
Here we report what is to date the largest series of pediatric patients with purpura 
fulminans  (PF),  as  a  consequence  of  acute  protein  C  pathway  failure  in  sepsis, 
treated with PC concentrate. In the majority of patients, the underlying infection was 
identified as meningococcemia. Protein C substitution was well tolerated, safe and 
the  need  for  amputations  and  skin  grafts  with  5.3%  and  9.6%  respectively,  both 
markedly lower than previously reported in children with PF. 
 
PF, if associated with septic shock, is a devastating disease carrying a high mortality 
and significant morbidity. While improvement in health care delivery for these very 
sick patients has dramatically improved survival in recent years [11, 12], permanent 
disability  as  a  result  of  amputation  of  limbs  or  digits,  extensive  scarring,  or 
neurological  injury  remains  problematic.  Gurgey  et  al.  reported  a  series  of  16 
children, nine (69%) of the 13 children 4 years of age or younger and one of the older 
children  (33%)  required  amputation  [13].  A  case  series  of  Wheeler  et  al.  on  21 
patients reported amputations in 9 (43%) [14]. Recent data from Rotterdam reports 
amputations  in  8%,  skin  grafts  in  16%  and  skin  scarring  in  48%  of  survivors  of 
meningococcal  disease  with  PF,  combined with  orthopedic  sequelae  in  14%  [15]. 
These  patients  did  not  receive  Protein  C.  In  5  patients  treated  in  a  burn  center 
including therapy with activated Protein C (aPC), an impressive 100% survival was 
achieved, however, amputations were still needed in 2 of the 5 children (40%) [16].  
 
We  and  others  have  previously  described  replacement  therapy  with  human,  non-
activated protein C in patients with meningococcemia in case reports and smaller 
case series [3, 4, 6, 17-19]. Other studies have explored the use of activated protein 
C in patients with PF. Vincent et al. published a post-hoc analysis of recent studies 
using  activated  protein  C  (aPC,  Xigris,  Ely  Lilly  Nederland  B.V.,  Houten, 
Netherlands)  in  adult  and  pediatric  patients  with  severe  sepsis,  presenting  with 
purpura fulminans, meningitis or meningococcal disease [5].  The authors identified 
119 pediatric patients suitable for the analysis, 87 of them with PF. In that group, 
which had a comparable incidence of coagulopathy and low protein C plasma levels, 
but a slightly more severe thrombocytopenia compared to the group reported here 
(85; 42 – 122 vs. 110; 66 – 183 G/l median; q1 – q3), serious bleeding events were 
noticed in 2 patients during the infusion and in 6 patients over a 28 day period. 14-   
day mortality was 9.4%, which is probably lower than the 22.3% in-hospital mortality 
in the group reported here. It is difficult to compare the illness severity of these two 
groups, since Vincent and co-workers did not report the rates for amputation or skin 
grafts. Another study, investigating the use of aPC in children with severe sepsis, 
which was terminated prematurely due to lack of efficacy, showed an increased rate 
of  hemorrhage  in  the  aPC  compared  to  the  placebo  group,  especially  in  children 
younger than 60 days [20].  
In contrast, significant bleeding complications were not seen in our large group of 
pediatric patients and have also not been associated with the use of human, non-
activated Protein C concentrate in adult studies so far.  
 
As  published  previously,  this  study  confirmed  low  plasma  protein  C  levels  to  be 
associated with negative outcome [21]. In fact, even a difference as small as one 
percent  in  protein  C  plasma  activity  at  admission  changed  the  odds  of  survival 
significantly. For a number of medical conditions, minimizing the amount of time from 
patient presentation to initiation of treatment represents an important consideration in 
the improvement of treatment outcomes. Analysis of a large, hospital-level database 
suggested  that  earlier  treatment  with  APC  is  associated  with  a  lower  in  hospital 
mortality in patients (n = 1179) with severe sepsis [22]. Another retrospective study, 
analyzing adults with severe sepsis and APC treatment found an increase in mortality 
from 33% if treated on the day of diagnosis to 40% if treatment was delayed by one 
day and to 52% if treatment was delayed by 2 days or more [23].  In our analysis, the 
interval between admission to ICU and the commencement of Protein C replacement 
therapy  was  significantly  longer  in  patients  who  died  compared  to  those  who 
survived,  which  may  point  towards  the  benefits  of  early  therapy  in  this  rapidly 
progressive condition. 
 
During  PC  therapy,  coagulatory  and  inflammatory  markers  may  be  important 
prognostic  markers.  The  prevalence  of  ongoing  coagulopathy,  as  reflected  in  a 
significantly  more  abnormal  aPTT  and  prothrombin  time  (PT),  and  in  significantly 
lower fibrinogen levels at admission and during therapy, was higher in non-survivors 
compared to survivors. During therapy, but not at admission, platelets were found to 
be significantly lower in patients who did not survive, also pointing towards ongoing 
coagulopathy  as  a  negative  prognostic  marker.  Interestingly,  while  non-survivors    
showed  lower  protein  C  plasma  levels  and  higher  incidence of coagulopathy,  the 
inflammatory response in terms of CRP levels and leukocytosis was less marked in 
the non-survivors, which could imply a degree of immuno-paralysis in those patients.  
 
Being a retrospective multi-center analysis, the limitations of this study are obvious: 
the lack of a control group and a prospective design makes it impossible to comment 
of the effects of PC on survival. The patients were treated in many different centers 
with a consequently large potential for intra-observer variability. On the other hand, 
the fact that even with so may different centers and protocols involved, the safety 
profile was still favorable in this unselected high risk population is very encouraging.  
 
Conclusions 
This study shows encouragingly low rates of amputations and skin grafts in a large 
group of pediatric patients with PF, combined with improvement or resolution of PF in 
most of the patients across all pediatric age groups, with no significant adverse side 
effects.  Our  study  supports  the  biological  rationale  of  human  non-activated  PC 
concentrate as a treatment for severe acquired protein C deficiency, presenting with 
purpura fulminans. Future studies investigating the effect of human, non-activated 
Protein C concentrate should focus on the potential benefit of early Protein C therapy 
in  PF,  and  amputations  and  skin  grafts  as  important  outcome  measures  in  this 
condition, which, despite recent advances in mortality control, still carries a high risk 
of disabling long-term morbidity. 
 
Key messages 
•  Low  plasma  levels  of  Protein  C  are  negatively  correlated  with  survival  in 
patients with PF in the context of meningococcemia. 
•  In  this  group  of  pediatric  patients,  substitution  with  human,  non-activated 
Protein  C  concentrate  resulted  in  an  improvement  of  PF  in  the  majority  of 
patients, without causing significant bleeding.  
•  The  need  for  amputations  and  skin  grafts  was  low  compared  to  historical 
controls, but there was no obvious effect on mortality. 
•  Future  studies  investigating  the  effect  of  human,  non-activated  Protein  C 
concentrate should focus on early Protein C therapy in PF, with amputations 
and skin grafts as important outcome parameters.    
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Figure legend 
Figure 1. Flow of patients through the study and exclusions of patients. The 
diagnosis of Purpura fulminans (PF) was regarded as definite in the presence of: livid 
to partly necrotic lesions of irregular shape and with sharp, clearly defined borders 
with either rapid progression or already ubiquitous appearance. The diagnosis of PF 
was  regarded  as  probable  in  the  presence  of:  livid  to  partly  necrotic  lesions  of 
irregular shape and with sharp, clearly defined borders. The diagnosis of PF was 
regarded as unclear in the presence of just livid to partly necrotic lesions without any 
of  the  other  criteria.  The  diagnosis  of  PF  was  not  confirmed  in  any  patient  with 
lesions not fulfilling the above defined criteria. PC: Protein C. 
    
Table 1: Clinical and laboratory parameters of all patients, survivors, non-
survivors before and during treatment with protein C concentrate 
 
 
All  Survived 
[n = 73] 
Died 
[n = 21] 
P 
Male/Female 
[n] 
52/42  42/31  10/11  n.s. 
Age 
[years] 
2.46  2.93  1.69  n.s. 
PC treatment 
PC total dose 
[IU] 
258.8 (127.6 – 410.9)  277.8 (132.4 – 444.4)  153.8 (126.0 – 375.0)  n.s. 
PC daily dose 
[IU/d] 
100 (73.4 – 136.6)  100  
(78.74 – 133.3)  
81.08 (71.09 – 153.8)  n.s. 
PC therapy duration [d]  2 
(1 – 4) 
3 
(2 – 4) 
2 
(1 – 4) 
n.s. 
Bolus/  
Bolus+cont. inf. 
78/16  61/12  17/4  n.s. 
Haematological paramenters prior to PC treatment 
WBC 
[pl] 
10.4 
(5.0 – 17.02) 
11.3 
(5.3 – 18.7) 
7.21 
(4.6 – 10.75) 
n.s (0.062) 
CRP 
[mg/dl] 
10.48 
(5.65 – 16.47) 
11.6 
(7.81 – 17.31) 
5.9 
(1.99 – 8.92) 
0.0018 
Platelets 
[G/l] 
110 
(66 – 183) 
116 
(74 – 182) 
78 
(52 – 178) 
n.s. 
PT 
[%] 
41 
(32 – 54) 
44 
(33 – 56) 
31 
(22 – 36) 
<0.001 
aPTT 
[sec.] 
59 
(43 – 91) 
52 
(39 – 71) 
108 
(81 – 160) 
<0.001 
Fibrinogen 
[mg/dl] 
270 
(174 – 440) 
347 
(217 – 503) 
129 
(82 – 202) 
<0.001 
D-Dimers 
[mg/l] 
2.38 
(0.93 – 8.99) 
2.13 
(0.89 – 8.62) 
6.40 
(1.08 – 12.00) 
n.s. 
AT 
[%] 
76 
(57 – 87) 
80 
(60 – 88) 
70 
(46 – 80) 
n.s. 
PC 
[%] 
27 
(14 – 39) 
30 
(18 – 41) 
10 
(10 – 18) 
<0.05 
Haematological parameters  during PC treatment 
WBC 
[pl] 
21.25 
(12.75 – 27.28) 
23.65 
(13.65 – 28.75) 
16.35  
(7.7 – 20.90) 
<0.05 
CRP 
[mg/dl] 
14.70 (7.0 – 21.8)  15.91  
(7.1 – 23.64) 
9.36 
(6.90 – 15.88) 
n.s. 
Platelets 
[G/l] 
96 
(57 – 130) 
103 
(65.5 – 136.5) 
61 
(30 – 80.75) 
<0.01 
PT 
[%] 
69 
(48.5 – 87) 
77.8 
(55 – 91) 
45.5 
(37.75 – 55.75) 
<0.01 
aPTT 
[sec.] 
43 
(33 – 52.75) 
41 
(33 – 47) 
61  
(47.5 – 88.4) 
<0.01 
Fibrinogen 
[mg/dl] 
558.5 
(342 – 747.2) 
600.5 
(418 – 766) 
214.5 
(184 – 299.2) 
<0.01 
D-Dimers 
[mg/l] 
1.95 
(0.8 – 6.16) 
1.6 
(0.68 – 5.96) 
2.93 
(1.14 – 6.4) 
n.s. 
AT 
[%] 
87 
(68.5 – 102.2) 
87 
(68 – 101.5) 
78 
(70 – 102) 
n.s. 
PC 
[%] 
71 
(53.5 – 108.4) 
79 
(54.7 – 106.8) 
68.5 
(33.75 – 108.5) 
n.s. 
 
Data on patient characteristics, outcome and laboratory findings. Shown as median 
and inter-quartile range (range between 1
st and 3
rd quartile). n.s. = not significant. 
Note that not all laboratory parameters could be obtained in all patients at each time-
point. PC – Protein C; WBC – white blood cell count; CRP  - C reactive protein; PT – 
prothrombin time; aPTT – activated partial thromboplastin time; AT  - antithrombin. Figure 1